High-throughput screening assay for sphingosine kinase inhibitors in whole blood using RapidFire® mass spectrometry

30Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

To facilitate discovery of compounds modulating sphingosine-1-phosphate (S1P) signaling, the authors used high-throughput mass spectrometry technology to measure S1P formation in human whole blood. Since blood contains endogenous sphingosine (SPH) and S1P, mass spectrometry was chosen to detect the conversion of an exogenously added 17-carbon-long variant of sphingosine, C17SPH, into C17S1P. The authors developed procedures to achieve homogeneous mixing of whole blood in 384-well plates and for a method requiring minimal manipulations to extract S1P from blood in 96- and 384-well plates prior to analyses using the RapidFire® mass spectrometry system. © 2011 Society for Laboratory Automation and Screening.

Cite

CITATION STYLE

APA

Highkin, M. K., Yates, M. P., Nemirovskiy, O. V., Lamarr, W. A., Munie, G. E., Rains, J. W., … Nagiec, M. M. (2011). High-throughput screening assay for sphingosine kinase inhibitors in whole blood using RapidFire® mass spectrometry. Journal of Biomolecular Screening, 16(2), 272–277. https://doi.org/10.1177/1087057110391656

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free